Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Cel-Sci Corporation (CVM : AMEX)
 
 • Company Description   
CEL-SCI CORP. was formed to acquire and finance research and development of natural human interleukin-2 (``IL-2``) and lymphokine-related products and processes using the Co.'s proprietary cell culture technologies. The Co.'s proprietary product is sometimes referred to as MULTIKINEn, or buffy-coat interleukins, which is a combination, or ``cocktail`` of IL-2 and certain lymphokines and cytokines. MULTIKINE is a trade name of Co. Since its inception the focus of the Co.'s product development efforts has been on conducting clinical trials to test its proprietary technologies.

Number of Employees:

 
 • Price / Volume Information   
Yesterday's Closing Price: $22.81 Daily Weekly Monthly
20 Day Moving Average: 768,639 shares
Shares Outstanding: 41.13 (millions)
Market Capitalization: $938.15 (millions)
Beta: 2.24
52 Week High: $40.91
52 Week Low: $10.76
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 5.60% 4.46%
12 Week 49.97% 40.46%
Year To Date 95.63% 73.22%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
8229 BOONE BLVD . SUITE 802
-
VIENNA,VA 22182
USA
ph: 703-506-9460
fax: 703-506-9471
gdewindt@cel-sci.com http://www.cel-sci.com
 
 • General Corporate Information   
Officers
Geert Kersten - Chief Executive Officer
Patricia B. Prichep - Senior Vice President of Operations and Corporate
Peter R. Young - Director
Bruno Baillavoine - Director
Robert Watson - Director

Peer Information
Cel-Sci Corporation (CORR.)
Cel-Sci Corporation (RSPI)
Cel-Sci Corporation (CGXP)
Cel-Sci Corporation (BGEN)
Cel-Sci Corporation (GTBP)
Cel-Sci Corporation (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 150837607
SIC: 2836
Fiscal Year
Fiscal Year End: September
Last Reported Quarter: 03/01/21
Next Expected EPS Date: 08/10/21
Share - Related Items
Shares Outstanding: 41.13
Most Recent Split Date: 6.00 (0.04:1)
Beta: 2.24
Market Capitalization: $938.15 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.13 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.64 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/10/21  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 31.52
Price/Cash Flow: -
Price / Sales: 1,675.27
EPS Growth
vs. Year Ago Period: -17.65%
vs. Previous Quarter: 4.76%
Sales Growth
vs. Year Ago Period: -62.34%
vs. Previous Quarter: -85.20%
ROE
03/31/21 - -129.71
12/31/20 - -142.49
09/30/20 - -170.96
ROA
03/31/21 - -70.24
12/31/20 - -69.77
09/30/20 - -71.38
Current Ratio
03/31/21 - 3.41
12/31/20 - 3.23
09/30/20 - 4.15
Quick Ratio
03/31/21 - 3.16
12/31/20 - 3.07
09/30/20 - 3.96
Operating Margin
03/31/21 - -
12/31/20 - -
09/30/20 - -4,862.14
Net Margin
03/31/21 - -
12/31/20 - -
09/30/20 - -5,406.61
Pre-Tax Margin
03/31/21 - -15,499.56
12/31/20 - -6,233.02
09/30/20 - -5,412.34
Book Value
03/31/21 - 0.72
12/31/20 - 0.73
09/30/20 - 0.51
Inventory Turnover
03/31/21 - 0.00
12/31/20 - 0.00
09/30/20 - 0.00
Debt-to-Equity
03/31/21 - 0.41
12/31/20 - 0.40
09/30/20 - 0.60
Debt-to-Capital
03/31/21 - 29.13
12/31/20 - 28.50
09/30/20 - 37.33
 

Powered by Zacks Investment Research ©